Amarin Corporation plc (AMRN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Amarin Corporation plc is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA globally through partnerships. The company operates as a single segment. In June 2025, Amarin executed an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA in 59 European countries, transitioning European commercial operations to Recordati.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in millions) |
|---|---|
| Total Revenue, Net | $87.3 |
| Product Revenue, Net | $82.4 |
| Licensing and Royalty Revenue | $4.9 |
| Gross Margin | $32.8 (34% of product revenue) |
| Operating Loss | $(23.3) |
| Net Loss | $(18.2) |
| Net Loss Per Share (Diluted) | $(0.04) |
| Cash and Cash Equivalents | $143.6 |
| Short-term Investments | $171.1 |
| Total Liquidity | $314.7 |
| Debt | $0 (No debt outstanding) |
| Net Cash Provided by Operating Activities | $13.0 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 24% year-over-year (YoY) to $87.3 million. This was driven primarily by a $22.2 million decrease in licensing revenue due to the absence of the $25.0 million upfront payment from the Recordati agreement recognized in the prior year. Product revenue decreased 6% to $82.4 million.
- Improved Profitability: Net loss improved significantly to $18.2 million from $29.8 million in the prior year period. Operating loss narrowed to $23.3 million from $32.7 million.
- Cost Reductions: Selling, general, and administrative (SG&A) expenses dropped 42% to $43.3 million, largely due to the Global Restructuring Plan and the transition of European commercial roles to Recordati. Restructuring expenses were $3.4 million compared to $22.8 million in the prior year.
- Gross Margin Compression: Gross margin percentage on product sales decreased to 34% from 55% in the prior year, attributed to a change in customer mix and lower net selling prices in the U.S.
- Market Share Growth: Despite revenue declines, Amarin's share of the U.S. IPE market increased to approximately 49% (from 42% YoY), and branded VASCEPA prescriptions increased 19% YoY.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue competitively managing market leadership in the U.S. and driving expanded access globally through partners. The company anticipates continued support for pricing and reimbursement initiatives in non-U.S. geographies.
- Liquidity: With $314.7 million in cash and investments and no debt, management believes resources are sufficient to fund operations for at least the next 12 months. A $50 million share repurchase program is authorized but has not yet commenced.
- Legal Proceedings:
- Antitrust Settlement: The company settled six putative antitrust class action lawsuits in April 2026. The settlement payment was recognized in Q1 2026 and settled in Q2 2026.
- Hikma Litigation: The U.S. Supreme Court reversed a lower court decision in June 2026, ruling that Amarin failed to state a claim for active inducement of patent infringement against Hikma. The case was remanded for further proceedings.
- Executive Litigation: Ongoing litigation with former CEO Karim Mikhail regarding alleged constructive termination; the company filed a motion to dismiss in February 2026.
- Generic Competition: Multiple generic versions of icosapent ethyl (IPE) are active in the U.S. market for the MARINE indication, impacting pricing and market dynamics.
Investor Verification Checklist
- Recordati Transition Impact: Verify the long-term revenue impact of transitioning European commercial operations to Recordati versus the one-time upfront payment recognized in 2025.
- U.S. Pricing Pressure: Assess the sustainability of the 34% gross margin given the increase in generic competition and the stated "change in customer mix."
- Antitrust Exposure: Monitor the status of the remanded Hikma case and any potential financial exposure from the settled class actions.
- Inventory Levels: Review the $164.1 million inventory balance (43% approved for North America) in the context of declining product revenue to assess obsolescence risk.
- Share Repurchase Activity: Track whether the company initiates the authorized $50 million share repurchase program given the current cash position.